Spike Protein News and Research

RSS

Swedish study reveals how long immunity lasts after mild COVID

As a result of the ongoing pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, the coronavirus disease 2019 (COVID-19), the global public health at risk has never been more dire.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won't protect against them.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

Study shows how SARS-CoV-2 virus enters cells to cause infection

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection.

24 Jun 2021

Researchers develop a low-cost automated rapid test for detecting SARS-CoV-2 antibodies

During the continued progression of the Corona pandemic, rapid, inexpensive, and reliable tests will become increasingly important to determine whether people have the associated antibodies - either through infection or vaccination.

24 Jun 2021

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.

24 Jun 2021

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

A new study describes the varying ways in which the virus co-opts the machinery of the host cell following infection to evade or modulate the host immune response, alter the pattern of translation of viral proteins, and the release of new viral particles.

24 Jun 2021

New tablet-sized device can profile multiple COVID-19 antibodies and biomarkers simultaneously

Biomedical engineers at Duke University in the USA have developed a device that detects coronavirus disease (COVID-19) antibodies as well as biomarkers that distinguish between antibodies produced in response to SARS-CoV-2 and four other coronaviruses with complete accuracy.

24 Jun 2021

Green tea catechins might be useful as pan-coronavirus inhibitors

Scientists from the Queen’s University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

A study of circulating biomarkers in hospitalized patients infected with SARS-CoV-2 alpha variant

Now, a new study published on the medRxiv* preprint server proposes a rapid method to identify the mutations in B.1.1.7 (N501Y mutation and H69/V70 deletion) and the impact of this variant on various biomarkers in hospitalized patients. This is the first study that correlates the biomarker levels to SARS-CoV-2 variants.

23 Jun 2021

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

Researchers in India have conducted a study showing that the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – was lower among people living with HIV and AIDS than among the general population.

23 Jun 2021

SARS-CoV-2 infection and transmission in the North American deer mouse

A recent study conducted in Canada reports that the North American deer mouse can be infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from humans.

23 Jun 2021

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Researchers have suggested that repeated vaccination against SARS-CoV-2 may enable previously uninfected individuals to cope with viral variants.

23 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Researchers found antibody levels in mRNA vaccinated individuals varied with age, gender, and previous coronavirus disease (COVID-19) infection.

23 Jun 2021

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

New research published in the journal Viruses suggests recovering from a coronavirus disease 2019 (COVID-19) infection provides immunity against the B.1.1.7 (or UK) variant. The time when the previous infection took place and the variant involved in prior infection influenced cross-neutralization.

23 Jun 2021

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Research led by Xin Zheng of Huazhong University of Science and Technology in Wuhan, China, found that about 90% of patients who recovered from COVID-19 continued to have IgG antibodies targeting the N-domain and receptor-binding domain of the spike protein. However, approximately 43% of patients showed signs of neutralizing antibody activity.

23 Jun 2021

Spike Protein News and Research

Swedish study reveals how long immunity lasts after mild COVID

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Study shows how SARS-CoV-2 virus enters cells to cause infection

Researchers develop a low-cost automated rapid test for detecting SARS-CoV-2 antibodies

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

New tablet-sized device can profile multiple COVID-19 antibodies and biomarkers simultaneously

Green tea catechins might be useful as pan-coronavirus inhibitors

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A study of circulating biomarkers in hospitalized patients infected with SARS-CoV-2 alpha variant

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

SARS-CoV-2 infection and transmission in the North American deer mouse

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News